about
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markersγ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes StudyWere James Bond's drinks shaken because of alcohol induced tremor?Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.Prediction, prevention and management of postresection liver failure.Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stemDirect targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography.F2-isoprostanes and the liver.Evaluation of area-based collagen scoring by nonlinear microscopy in chronic hepatitis C-induced liver fibrosis.Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis.Performance of serum marker panels for liver fibrosis in chronic hepatitis C.Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver diseaseResolving fibrosis in the diseased liver: translating the scientific promise to the clinic.Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging.Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?Non-invasive monitoring of liver fibrosis.Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.Screening for liver fibrosis in the general population: a call for action.Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.A study of T₁ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors.Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis.Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value?Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study.Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis.The effect of prone positioning with surgical bolsters on liver blood flow in healthy volunteers.Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease.Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage.The detection of oesophageal varices using a novel, disposable, probe-based transnasal endoscope: a prospective diagnostic pilot study.Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease.SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosisBiomarkers of liver fibrosisAnalysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver diseaseNon-invasive tests for the detection of oesophageal varices in compensated cirrhosis: systematic review and meta-analysis.
P50
Q28258678-80B8F479-85D7-4D7A-8C52-365A2BD7BB6AQ28648219-CF5D3A99-E1F6-4249-82CA-D19515A770B9Q28660406-FCD7020E-8974-4171-BA2B-CB3CB3524C40Q30234829-41735F05-DAB2-4211-93CC-D7B9BC779B1DQ33949776-DE8F4996-6019-4E43-B44D-A5E9918618D4Q34476310-00C59ABB-0991-4196-9D41-649E60FA624DQ35203746-83065D56-3A0A-4EAE-9116-F036FAD5C8EFQ35573240-5DC82746-70E8-4C0C-9E63-D73D1D1C2694Q35588475-52E5E80A-BC22-4C95-8E87-BD4B58309C41Q35613412-685E3731-CD2B-4BAB-9674-92BE49BE7DA6Q35775791-F25AA028-D251-401D-B949-735838070829Q36373907-E1472431-7D49-466B-A17C-6B1EEF22C0A8Q36643026-F6B312BB-3351-4595-8F6A-2906EAB8F19EQ36655445-86ED0ED1-0374-4B1D-A43E-225D1F086EC7Q36750183-FDBF46BB-C3FD-4E37-9C72-85B0D6AA6188Q36801010-C5D6BE79-9005-4580-8CE1-53924A7D1355Q37441985-F71FBC80-1155-495B-9DAD-5E16D54129F1Q37897194-AF7F4116-C6CE-4BC5-AEB5-036952D2DF55Q38262486-EF4F317D-C9D5-4944-A95E-FCB0CCF306ECQ38692351-89987493-02DA-4FF6-A768-41D475EAE1EBQ38839769-C6C5BAA6-285D-420C-80FB-8F39CF1BF772Q39253135-6BF87A49-2C52-4329-8A43-F0198F6BDD6FQ41020416-9AA487DD-3CDC-4A59-B3A3-2ACBB6117C99Q41658253-91A93BE0-B14C-4C71-AB48-CC522B7085F0Q43604235-A3A137DA-DF0C-4C06-BBAD-9D51C18CC605Q43870964-BBC78D09-C14E-49C5-8FED-8FFD514ABBA9Q45402850-E9FBC22B-AFF3-4F46-9633-0A2393B2D611Q47109230-3244168F-9E96-4EB8-A377-D8EE7B40A84EQ47129673-2727A993-7BCC-46F5-B1B8-34C470BBABF2Q47581867-BC501ED2-51A2-40C3-B5CA-8668F86D4FEBQ48170286-81DBD8E9-C56E-4576-B3C7-24835289AF55Q49719507-14ED59E8-09F0-4B7D-8775-64C31F30233DQ51307502-7E08E09F-C077-4870-B55C-9903FF548714Q51353027-A150C6B2-99C2-45DB-8BF9-0DDCF07AA0CCQ51717108-A4CB3939-C755-4F29-9247-69C5E486D599Q51814750-09ABF693-925C-479A-81C8-5542003A7034Q60301844-EDC643E7-5763-444B-AF8F-15658D8EAF25Q62626273-58D5D2DD-2D46-46CB-AACF-7F3F8617EB20Q63437084-0E87F2A2-296E-4344-AD06-A2F934D81269Q64929410-5BD617AD-C999-48AD-ABF2-7C16A568E1FC
P50
description
researcher ORCID ID = 0000-0002-6940-5861
@en
wetenschapper
@nl
name
Indra N Guha
@ast
Indra N Guha
@en
Indra N Guha
@es
Indra N Guha
@nl
type
label
Indra N Guha
@ast
Indra N Guha
@en
Indra N Guha
@es
Indra N Guha
@nl
altLabel
Guha IN
@en
Indra Neil Guha
@en
prefLabel
Indra N Guha
@ast
Indra N Guha
@en
Indra N Guha
@es
Indra N Guha
@nl
P106
P1153
12242268700
P31
P496
0000-0002-6940-5861